159 related articles for article (PubMed ID: 33558179)
21. Cost-effectiveness of adding an electron-beam boost to tangential radiation therapy in patients with negative margins after conservative surgery for early-stage breast cancer.
Hayman JA; Hillner BE; Harris JR; Pierce LJ; Weeks JC
J Clin Oncol; 2000 Jan; 18(2):287-95. PubMed ID: 10637242
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.
Sherman SK; Lange JJ; Dahdaleh FS; Rajeev R; Gamblin TC; Polite BN; Turaga KK
JAMA Oncol; 2019 Feb; 5(2):236-242. PubMed ID: 30489611
[TBL] [Abstract][Full Text] [Related]
23. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Analysis of No Adjuvant Therapy Versus Partial Breast Irradiation Alone Versus Combined Treatment for Treatment of Low-Risk DCIS: A Microsimulation.
Ward MC; Vicini F; Al-Hilli Z; Chadha M; Abraham A; Recht A; Hayman J; Thaker N; Khan AJ; Keisch M; Shah C
JCO Oncol Pract; 2021 Aug; 17(8):e1055-e1074. PubMed ID: 33970684
[TBL] [Abstract][Full Text] [Related]
25. Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer From a US Payer Perspective.
Xie J; Hao Y; Zhou ZY; Qi CZ; De G; Glück S
Clin Breast Cancer; 2015 Oct; 15(5):e263-76. PubMed ID: 26048087
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of six months versus 1-year adjuvant trastuzumab in HER2 positive early breast cancer in Egypt.
Elsisi GH; Nada Y; Rashad N; Carapinha J; Noor AO; Almasri DM; Zaidy MA; Foad A; Khaled H
J Med Econ; 2020 Jun; 23(6):575-580. PubMed ID: 32011199
[No Abstract] [Full Text] [Related]
27. Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.
Ito K; Elkin E; Blinder V; Keating N; Choudhry N
Cancer; 2013 Jul; 119(13):2494-502. PubMed ID: 23775433
[TBL] [Abstract][Full Text] [Related]
28. Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer.
Ali AA; Tawk R; Xiao H; Semykina A; Montero AJ; Moussa RK; Popoola O; Diaby V
Expert Rev Pharmacoecon Outcomes Res; 2022 Jul; 22(5):735-741. PubMed ID: 35189767
[TBL] [Abstract][Full Text] [Related]
29. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
[TBL] [Abstract][Full Text] [Related]
31. Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer.
Lipsitz M; Delea TE; Guo A
Curr Med Res Opin; 2010 Oct; 26(10):2315-28. PubMed ID: 20731528
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast.
Suh WW; Hillner BE; Pierce LJ; Hayman JA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1054-61. PubMed ID: 15752884
[TBL] [Abstract][Full Text] [Related]
33. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
Delea TE; El-Ouagari K; Karnon J; Sofrygin O
Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
[TBL] [Abstract][Full Text] [Related]
35. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of routine radiation therapy following conservative surgery for early-stage breast cancer.
Hayman JA; Hillner BE; Harris JR; Weeks JC
J Clin Oncol; 1998 Mar; 16(3):1022-9. PubMed ID: 9508186
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of a 21-gene recurrence score assay versus Canadian clinical practice in women with early-stage estrogen- or progesterone-receptor-positive, axillary lymph-node negative breast cancer.
Hannouf MB; Xie B; Brackstone M; Zaric GS
BMC Cancer; 2012 Oct; 12():447. PubMed ID: 23031196
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness Analysis of CYP2D6*10 Pharmacogenetic Testing to Guide the Adjuvant Endocrine Therapy for Postmenopausal Women with Estrogen Receptor Positive Early Breast Cancer in China.
Wei X; Sun H; Zhuang J; Weng X; Zheng B; Lin Q; Zhang G; Cai J
Clin Drug Investig; 2020 Jan; 40(1):25-32. PubMed ID: 31559573
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness assessment of lumpectomy cavity boost in elderly women with early stage estrogen receptor positive breast cancer receiving adjuvant radiotherapy.
Lester-Coll NH; Rutter CE; Evans SB
Radiother Oncol; 2016 Apr; 119(1):52-6. PubMed ID: 26867968
[TBL] [Abstract][Full Text] [Related]
40. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]